Prime Stock recommendation: A steady player in the challenging API business
Pharma companies in the API (Active Pharmaceutical Ingredient) space in India have struggled in the past couple of years, confronted by rising input costs, poor price realization and competition from China even while remaining dependent on China for inputs. All these also impact the even-otherwise modest margins.
Some of these challenges appear to be abating, providing an opportunity to pick select API players in the pharma space.
Premium article available only to subscribers.
Prime Stock recommendation: A steady player in the challenging API business Read More »